Bortezomib-induced peripheral neuropathy (BiPN) occurs in approximately 40% of patients
with multiple myeloma. The induction of severe neuropathy entails the dose reduction or …

Multiple myeloma (MM) is a B cell neoplasm characterized by uncontrolled growth of
malignant plasma cells within the bone marrow. The introduction of new treatment regimens …

Background Bortezomib results in peripheral neuropathy (PN) in approximately 50% of
patients, during multiple myeloma (MM) treatment, a complication known as Bortezomib …

The proteasome‐inhibitor bortezomib was introduced into the treatment of multiple myeloma
more than a decade ago. It is clinically beneficial, but peripheral neuropathy (PNP) is a side …

Background Bortezomib-induced peripheral neuropathy is a dose-limiting toxicity in patients
with multiple myeloma, often requiring adjustment of treatment and affecting quality of life …

The proteasome inhibitor bortezomib (BTZ) is a first-line antitumor drug, mainly used for
multiple myeloma treatment. However, BTZ shows prominent toxicity in the peripheral …

Purpose: Painful peripheral neuropathy is a frequent toxicity associated with bortezomib
therapy. This study aimed to identify loci that affect susceptibility to this toxicity. Experimental …

Bortezomib is the first-line standard and most effective chemotherapeutic for multiple
myeloma; however, bortezomib-induced peripheral neuropathy (BIPN) severely affects the …

Bortezomib, a proteasome inhibitor, has been considered as a promising anticancer drug in
the treatment of recurrent multiple myeloma and some solid tumors. The bortezomib …

A subanalysis of the GIMEMA‐MMY‐3006 trial was performed to characterize treatment‐
emergent peripheral neuropathy (PN) in patients randomized to thalidomide …